Related Experiment Videos
Novel therapeutic approaches for multiple myeloma
Teru Hideshima1, Paul Richardson, Kenneth C Anderson
1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Immunological Reviews
|July 9, 2003
Summary
Multiple myeloma, an incurable blood cancer, involves complex interactions within the bone marrow microenvironment. Targeting these MM-host interactions with novel therapies shows promise in overcoming drug resistance.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Multiple myeloma (MM) is a significant hematologic malignancy affecting numerous patients annually and remains incurable.
- The bone marrow microenvironment plays a critical role in MM cell survival, growth, and drug resistance.
- Understanding MM-host interactions is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To investigate the role of MM-host interactions in regulating MM cell behavior within the bone marrow.
- To explore the potential of targeting these interactions to overcome drug resistance in multiple myeloma.
Main Methods:
- Preliminary in vitro studies utilizing MM cell lines.
- In vivo animal models to assess MM progression and treatment response.
- Evaluation of drug resistance mechanisms in the context of the bone marrow microenvironment.
Main Results:
- Preliminary data suggest that MM-host interactions significantly influence MM cell growth, drug resistance, and migration.
- Targeting specific MM-host interaction mechanisms shows potential in preclinical models.
- Therapies like thalidomide derivatives and proteasome inhibitors demonstrate efficacy in overcoming drug resistance.
Conclusions:
- MM-host interactions are key regulators of multiple myeloma progression and therapeutic response.
- Targeting the bone marrow microenvironment offers a promising avenue for novel MM treatments.
- Emerging therapies targeting these interactions show potential to overcome drug resistance in MM.